The U.S. Food and Drug Administration has approved the trade name Auryxia for Keryx Biopharmaceuticals’ ferric citrate. Auryxia, an iron-based phosphate binder, was approved by the FDA to control serum phosphorus levels in patients with chronic kidney disease on dialysis in September 2014.

Ron Bentsur, Chief Executive Officer of Keryx, commented, “We are excited to receive FDA approval of the trade name Auryxia. We look forward to launching Auryxia in the U.S. at year end and to providing nephrologists with an effective phosphate binder for dialysis-dependent CKD patients.”